Previous Webinar

Mat Todd is Professor and Chair of Drug Discovery of the School of Pharmacy at University College London. His research interests include the development of new ways to make molecules, particularly how to make chiral molecules with new catalysts. He has a significant interest in open science, and how it may be used to accelerate research, with particular emphasis on open source discovery of new medicines.

Ben Perry is Open Innovation Leader at Drugs for Neglected Diseases initiative (DNDi). Ben is a medicinal chemist with over 15 years’ experience conducting early stage drug discovery across a variety of disease indications including oncology, autoimmune disorders, and psychiatry.

Lauren Webster is the WCAIR Scientific and Pedagogy Lead at the University of Dundee. The Wellcome Centre for Anti-Infectives Research (WCAIR) is a hub for neglected tropical disease drug discovery at the University of Dundee and was launched in 2017. WCAIR focuses activities in the three areas research, training, and public engagement. Lauren is a medicinal chemist by training with a strong interest in neglected diseases.

Ed J. Griffen obtained his Ph.D. from Imperial College, London, and undertook postdoctoral research at the University of Waterloo-Kitchener, Canada. He joined Zeneca Pharmaceuticals as a team leader in medicinal chemistry working in the CNS, infection, oncology, and chemical biology areas.

Bill Scott is a research professor in the chemistry and chemical biology department at Indiana University–Purdue University Indianapolis (IUPUI). He has extensive experience in both pharmaceutical and academic environments. The focus of his research is the development of simple and inexpensive equipment and combinatorial synthetic methodologies to quickly make large numbers of “drug-like” molecules that facilitate training projects for students.

Paul Workman is a multidisciplinary cancer research scientist, molecular pharmacologist and chemical biologist who has been responsible for the laboratory discovery and progression into the clinic of many innovative cancer drugs.